Internal Medicine, Rheumatology · Easton, MD
NPI
1104051945
Since 2009
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
505 Dutchmans Ln, Suite A2
Easton, MD, 21601
Phone (410) 819-6545
Groups this clinician bills Medicare through
Medicare paid, 2024
$10.0M
743,104 services
Medicare patients, 2024
1,994
Average age 74
Drug cost, 2024
$4.1M
2,408 prescriptions
Company payments, 2025
$24K
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Elizabeth S Clayton was code J0717 (injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)), 203,600 times for 59 patients. In total Elizabeth S Clayton billed 743,104 services in 74 codes, and Medicare paid $10.0M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2016-05-13.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J0717 Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 203,600 | 59 | $3.58 | $729K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 171,150 | 147 | $8.47 | $1.4M |
| J0897 Injection, denosumab, 1 mg | Office | 84,120 | 810 | $20.37 | $1.7M |
| J3262 Injection, tocilizumab, 1 mg | Office | 82,120 | 27 | $4.70 | $386K |
| J1306 Injection, inclisiran, 1 mg | Office | 42,032 | 86 | $9.48 | $398K |
| J3380 Injection, vedolizumab, intravenous, 1 mg | Office | 28,200 | 24 | $17.40 | $491K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 13,970 | 59 | $24.88 | $348K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 13,500 | 28 | $33.87 | $457K |
| J2350 Injection, ocrelizumab, 1 mg | Office | 9,300 | 12 | $46.84 | $436K |
| J3245 Injection, tildrakizumab, 1 mg | Office | 7,700 | 23 | $107.85 | $830K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 7,646 | 15 | $8.56 | $65K |
| J9312 Injection, rituximab, 10 mg | Office | 6,400 | 23 | $57.50 | $368K |
| 96401 Chemotherapy Administration | Office | 3,485 | 778 | $56.79 | $198K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 2,592 | 79 | $0.23 | $592 |
| 96413 Chemotherapy Administration | Office | 1,043 | 251 | $101.75 | $106K |
By year: 2022 $5.8M for 407,112 services; 2023 $8.5M for 651,794 services; 2024 $10.0M for 743,104 services.
Medicare prescription drug claims, 2024
In 2024, the drug Elizabeth S Clayton prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 327 prescriptions and refills. In total Elizabeth S Clayton wrote 2,408 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 327 | 900 | 116 | $19K |
| Prednisone Generic | 316 | 734 | 131 | $3,631 |
| Methotrexate Methotrexate Sodium | 197 | 445 | 62 | $8,140 |
| Tramadol Hcl Generic | 153 | 173 | 38 | $1,701 |
| Celecoxib Generic | 90 | 224 | 33 | $3,217 |
| Enbrel Sureclick Etanercept | 79 | 81 | 11 | $578K |
| Methylprednisolone Generic | 79 | 104 | 62 | $840 |
| Alendronate Sodium Generic | 68 | 188 | 27 | $901 |
| Gabapentin Generic | 59 | 104 | 18 | $1,453 |
| Leflunomide Generic | 57 | 122 | 24 | $4,929 |
| Pregabalin Generic | 42 | 79 | 14 | $3,803 |
| Xeljanz Xr Tofacitinib Citrate | 42 | 46 | Under 11 | $262K |
| Mycophenolate Mofetil Generic | 42 | 78 | Under 11 | $6,874 |
| Rinvoq Upadacitinib | 40 | 58 | Under 11 | $359K |
| Orencia Clickject Abatacept | 35 | 35 | Under 11 | $195K |
Brand drugs: 540 claims; generic drugs: 1,842 claims; opioid claims: 185.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Elizabeth S Clayton $24K ($24K in general payments such as food, travel and fees) from 21 companies. The largest payer was Abbvie Inc. with $19K.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 67 | $19K |
| Lilly USA, LLC LLY | 15 | $2,029 |
| Amgen Inc. AMGN | 26 | $681 |
| Mallinckrodt Hospital Products Inc. | 8 | $502 |
| AstraZeneca Pharmaceuticals LP AZN | 9 | $318 |
| ANI Pharmaceuticals, Inc. ANIP | 6 | $185 |
| UCB, Inc. UCB.BR | 6 | $174 |
| GlaxoSmithKline, LLC. GSK | 6 | $111 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $111 |
| Janssen Biotech, Inc. JNJ | 4 | $104 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.